کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10963473 | 1102684 | 2015 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
MZLLSSDLBCLMRDParRPLTDTHHspTTPimmunotherapy - ایمونوتراپیpartial remission - بهبودی جزئیprogressive disease - بیماری پیشرفتهdelayed-type hypersensitivity - تاخیر نوع حساسیت بالاPacked cell volume - حجم سلول بسته بندی شدهMinimal residual disease - حداقل بیماری باقی ماندهPeripheral blood - خون محیطیcomplete remission - رمی کاملTime to progression - زمان به پیشرفتWorld Health Organization - سازمان بهداشت جهانیDog - سگFlow cytometry - فلوسیتومتریlactate dehydrogenase - لاکتات دهیدروژناز LDH - لاکتات دهیدروژناز به صورت مختصر شده LDH Indolent lymphoma - لنفوم تندرستDiffuse large B-cell lymphoma - لنفوم سلول B بزرگ سلول بزرگFollicular lymphoma - لنفوم فولیکولارMarginal zone lymphoma - لنفوم ناحیه لگنbone marrow - مغز استخوانHydroxyapatite - هیدروکسی آپاتیتHeat shock protein - پروتئین شوک حرارتHeat shock proteins - پروتئینهای شوک حرارتیPlatelets - پلاکت هاPCV - پی وی سیWHO - کهLymph node - گره های لنفاوی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The aim of this non-randomized controlled trial was to compare time to progression (TTP), lymphoma-specific survival (LSS), and safety of an autologous vaccine (consisting of hydroxyapatite ceramic powder and Heat Shock Proteins purified from the dogs' tumors, HSPPCs-HA) plus chemotherapy versus chemotherapy alone in dogs with newly diagnosed, clinically advanced, histologically confirmed, multicentric indolent B-cell lymphoma. The vaccine was prepared from dogs' resected lymph nodes and administered as an intradermal injection. Forty-five client-owned dogs were enrolled: 20 dogs were treated with dose-intense chemotherapy, and 25 received concurrent immunotherapy. Both treatment arms were well tolerated, with no exacerbated toxicity in dogs also receiving the vaccine. TTP was significantly longer for dogs treated with chemo-immunotherapy versus those receiving chemotherapy only (median, 209 versus 85 days, respectively, PÂ =Â 0.015). LSS was not significantly different between groups: dogs treated with chemo-immunotherapy had a median survival of 349 days, and those treated with chemotherapy only had a median survival of 200 days (PÂ =Â 0.173). Among vaccinated dogs, those mounting an immune response had a significantly longer TTP and LSS than those with no detectable response (PÂ =Â 0.012 and PÂ =Â 0.003, respectively). Collectively these results demonstrate that vaccination with HSPPCs-HA may produce clinical benefits with no increased toxicity, thereby providing a strategy for enhancing chemotherapy in dogs with advanced indolent lymphoma.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 33, Issue 39, 22 September 2015, Pages 5080-5086
Journal: Vaccine - Volume 33, Issue 39, 22 September 2015, Pages 5080-5086
نویسندگان
L. Marconato, D. Stefanello, S. Sabattini, S. Comazzi, F. Riondato, P. Laganga, P. Frayssinet, S. Pizzoni, N. Rouquet, L. Aresu,